New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

While sales of the HIV therapy called Cabenuva also did not disappoint, totaling $396 million, up 23.8% quarter-on-quarter. GSK also raised its 2031 sales outlook to £40 billion from £38 billion.

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

and a contribution by recently-launched long-acting injectable Cabenuva (cabotegravir). On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £ ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

HIV sales rose 14% driven by strong demand and increased market share for oral two-drug regimens, Dovato and Juluca, and long-acting regimens like Cabenuva and Apretude. GSK generates the ...